5-Methyl-3-(pyridin-2-yl)benzo[5,6][1,2]thiazino[3,4-e][1,3]oxazine-2,4(3H,5H)-dione 6,6-dioxide

Names

[ Name ]:
5-Methyl-3-(pyridin-2-yl)benzo[5,6][1,2]thiazino[3,4-e][1,3]oxazine-2,4(3H,5H)-dione 6,6-dioxide

[Synonym ]:
Droxicam
2H,5H-1,3-Oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione, 5-methyl-3-(2-pyridinyl)-, 6,6-dioxide
5-methyl-6,6-dioxo-3-pyridin-2-yl-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4-dione
5-Methyl-3-(2-pyridinyl)-2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide
5-Methyl-3-(pyridin-2-yl)-2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide
Ombolan
5-Methyl-3-(2-pyridinyl)-2H,5H-1,3-oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-Dioxide
5-Methyl-3-(pyridin-2-yl)benzo[5,6][1,2]thiazino[3,4-e][1,3]oxazine-2,4(3H,5H)-dione 6,6-dioxide

Biological Activity

[Description]:

Droxicam (Ombolan) is a non-steroidal anti-inflammatory agent, with strong analgesic activity. Droxicam acts by inhibiting PGE2 varies, and is characterised by being a pro-drug of Piroxicam (HY-B0253). Droxicam is well tolerated with slight side effects in the said mucosa. Droxicam does not show cardiovascular or respiratory effects in cats, and inhibits peritoneal capillary permeability in mouse[1][2].

[Related Catalog]:

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

[In Vivo]

Droxicam (0.25 和 0.5 mg/kg；口服) 在角叉菜胶诱导的大鼠水肿中表现出高抗炎活性[1]。 Droxicam (ED50, p.o.; 5, 6, 7, 8 h; 7.5, 12.9, 4.8, 8.4 mg/kg) 在大鼠中对制霉菌素诱导的水肿表现出高抗炎活性[1]。 Droxicam (ED50，口服，1、2、3、4 小时：0.51、0.94、1.56、4.88 mg/kg) 对紫外线光诱导红斑的豚鼠，显示出保护作用[1]。 Droxicam (0.1 mg/kg, 0.33 mg/kg, 1 mg/kg; po; 每日一次) 在注射 Mycobacterium butyricum 的大鼠中显示出良好的抗关节炎活性，可抵抗原发性和继发性病变[1]。 Droxicam 在防止小鼠扭体方面表现出很强的镇痛活性，对由苯基苯醌诱导、乙酰胆碱溴化物诱导的小鼠，ED50 分别为 5.3 mg/kg 和 1.1 mg/kg[1]。 Droxicam (ED50=0.081 mg/kg; po) 保护大鼠免受蓖麻油引起的腹泻[1]。 Droxicam 显著抑制小鼠腹膜毛细血管通透性[1]。 Droxicam 在 Irwin 试验中，不会改变大鼠的行为 (80 mg/kg，i.p.) 和小鼠的行为 (160 mg/kg，p.o.)[1]。 Droxicam 在大鼠中不表现出排尿酸活性，在麻醉猫中既不表现出心血管或呼吸作用，也不改变它们对乙酰胆碱、去甲肾上腺素和组胺给药的反应[1]。

[References]

[1]. Farré AJ, et al. Pharmacological properties of droxicam, a new non-steroidal anti-inflammatory agent. Methods Find Exp Clin Pharmacol. 1986 Jul;8(7):407-22.

[2]. Jané F, et al. Droxicam: a pharmacological and clinical review of a new NSAID. Eur J Rheumatol Inflamm. 1991;11(4):3-9.

Chemical & Physical Properties

[ Density]:
1.7±0.1 g/cm3

[ Boiling Point ]:
554.7±60.0 °C at 760 mmHg

[ Melting Point ]:
259-261°

[ Molecular Formula ]:
C₁₆H₁₁N₃O₅S

[ Molecular Weight ]:
357.34

[ Flash Point ]:
289.3±32.9 °C

[ Exact Mass ]:
357.041931

[ PSA ]:
110.86000

[ LogP ]:
1.11

[ Vapour Pressure ]:
0.0±1.5 mmHg at 25°C

[ Index of Refraction ]:
1.748

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: RP6505000

CHEMICAL NAME :: 2H,5H-1,3-Oxazino(5,6-c)(1,2)benzothiazine-2,4(3H)-di one, 5-methyl-3-(2-pyridinyl)-, 6,6-dioxide

CAS REGISTRY NUMBER :: 90101-16-9

LAST UPDATED :: 199612

DATA ITEMS CITED :: 2

MOLECULAR FORMULA :: C16-H11-N3-O5-S

MOLECULAR WEIGHT :: 357.36

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1434 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4563452

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 6192 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4563452

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.